MacroGenics to Receive Milestone Payment from Sanofi for Recent TZIELD® Approval
MacroGenics announced it will receive a $24.5 million regulatory milestone payment from partner Sanofi following the FDA's accelerated approval of TZIELD for delaying insulin decline in children aged 8 to 17 with stage 3 type 1 diabetes. Under the collaboration agreement, MacroGenics remains eligible to receive up to $305 million in additional milestone payments and retains single-digit royalty rights on global net sales above a specified threshold.
Key figures
- Drug Name
- TZIELD (teplizumab-mzwv)
- Milestone payment
- 24500000
- Potential additional milestones
- 305000000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.